ArticleSaudi medical journal2026
Juvenile Idiopathic Arthritis Registry at King Abdullah Specialized Children's Hospital (JIAR-KASCH) in Riyadh, Saudi Arabia.
Article in Saudi medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo establish and maintain a comprehensive, up-to-date registry of juvenile idiopathic arthritis (JIA) cases, and to outline the methodology used in creating it.
methodsRetrospective and prospective data collection commenced in August 2021, using the Hospital Information System to identify electronic medical records of JIA patients. All individuals diagnosed with JIA and receiving follow-up care at King Abdullah Specialized Children's Hospital (KASCH) in Riyadh were included. A broad range of variables covering sociodemographic characteristics, clinical features, laboratory results, imaging findings, and therapeutic medications were recorded in the REDCap platform. Data collection update occurs every 6 months.
resultsBy December 2024, the registry included 240 patients. The median age at presentation was 8 years (IQR: 4-11). Most patients (79%) were from the central region of Saudi Arabia, while the remainder were distributed across other regions. Oligoarthritis was the most common subtype (32.9%), followed by systemic JIA (25.8%). Among the biologic agents used to treat JIA, anti-TNF agents were the most frequently administered (62.5%), followed by anakinra (17%) and tocilizumab (13%).
conclusionThe JIAR-KASCH provides an in-depth profile of JIA epidemiology, clinical presentation, and management in Saudi Arabia. It also provides a framework that can guide the development of similar national registries, particularly in pediatric rheumatology, facilitating robust data collection and long-term disease monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.